Annemette Vinding Thougaard

Annemette Vinding Thougaard

Auto-generated profile, based on publicly available information

Annemette Vinding Thougaard

Department of Exploratory Toxicology, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby, Denmark

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2009 in Blood
Verified
Journal Article
Open access
PDF file
ANAimable Nahimana
Aimable Nahimana
AAAntoine Attinger
Antoine Attinger
DADominique Aubry
Dominique Aubry
PGPeter Greaney
Peter Greaney
CIChristopher Ireson
Christopher Ireson
MDMichel A. Duchosal
Michel A. Duchosal
APO866 inhibits nicotinamide phosphoribosyltransferase (NMPRTase), a key enzyme involved in nicotinamide adenine dinucleotide (NAD) biosynthesis from the natural precursor nicotinamide. Intracellular NAD is essential for cell survival, and NAD depletion resulting from APO866 treatment elicits tumor cell death. Here, we determine the in vitro and in vivo sensitivities of hematologic cancer cells to APO866 using a panel of cell lines (n = 45) and primary cells (n = 32). Most cancer cells (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], mantle cell lymphoma [MCL], chronic lymphocytic leukemia [CLL], and T-cell lymphoma), but not normal hematopoietic progenitor cells, were sensitive to low concentrations of APO866 as measured in cytotoxicity and clonogenic assays. Treatment with APO866 decreased intracellular NAD and adenosine triphosphate (ATP) at 24 hours and 48 to72 hours, respectively. The NAD depletion led to cell death. At 96 hours, APO866-mediated cell death occurred in a caspase-independent mode, and was associated with mitochondrial dysfunction and autophagy. Further, in vivo administration of APO866 as a single agent prevented and abrogated tumor growth in animal models of human AML, lymphoblastic lymphoma, and leukemia without significant toxicity to the animals. The results support the potential of APO866 for treating hematologic malignancies.

1 March 2003 in Preventive Veterinary Medicine
Verified
Journal Article
Closed access
HSH Stege
H Stege
FBF Bager
F Bager
EJE Jacobsen
E Jacobsen
ATA Thougaard
A Thougaard

1 August 2006 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
XQXiaozhong Qian
Xiaozhong Qian
WLWilliam J. LaRochelle
William J. LaRochelle
GAGulshan Ara
Gulshan Ara
FWFrank Wu
Frank Wu
KPKamille Dumong Petersen
Kamille Dumong Petersen
MJMichael Jeffers
Michael Jeffers
Histone deacetylase inhibitors represent a promising new class of anticancer agents. In the current investigation, we examined the activity of PXD101, a potent histone deacetylase inhibitor, used alone or in combination with clinically relevant chemotherapeutics (docetaxel, paclitaxel, and carboplatin), in preclinical in vitro and in vivo models of ovarian cancer. In vitro activity was examined in ovarian cancer and multidrug-resistant cell lines grown in monolayer culture, and in primary clinical ovarian cancer specimens grown in three-dimensional organoid culture. PXD101 was found to inhibit in vitro cancer cell growth at sub- to low micromolar IC50 potency, exhibited synergistic activity when used in combination with relevant chemotherapeutics, and effectively inhibited the growth of multidrug-resistant cells. In vivo, PXD101 displayed single-agent antitumor activity on human A2780 ovarian cancer s.c. xenografts which was enhanced via combination therapy with carboplatin. In support of these findings, PXD101 was shown to increase the acetylation of α-tubulin induced by docetaxel and the phosphorylation of H2AX induced by carboplatin. Taken together, these results support the clinical evaluation of PXD101 used alone or in combination therapy for the treatment of ovarian cancer. [Mol Cancer Ther 2006;5(8):2086–95]

1 August 2014 in Drug Discovery Today
Verified
Journal Article
Closed access
JHJorrit J. Hornberg
Jorrit J. Hornberg
MLMorten Laursen
Morten Laursen
NBNina Brenden
Nina Brenden
MPMikael Persson
Mikael Persson
ATAnnemette V. Thougaard
Annemette V. Thougaard
TMTomas Mow
Tomas Mow

1 January 2009 in Toxicology
Verified
Journal Article
Closed access
EMElke Martin
Elke Martin
ATAnnemette Vinding Thougaard
Annemette Vinding Thougaard
MGMorten Grauslund
Morten Grauslund
PJPeter B. Jensen
Peter B. Jensen
FBFredrik Bjorkling
Fredrik Bjorkling
LJLars H. Jensen
Lars H. Jensen

1 June 2010 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
UOUffe Høgh Olesen
Uffe Høgh Olesen
ATAnnemette V. Thougaard
Annemette V. Thougaard
PJPeter Buhl Jensen
Peter Buhl Jensen
MSMaxwell Sehested
Maxwell Sehested
Inhibitor of nicotinamide phosphoribosyltransferase APO866 is a promising cancer drug currently in phase II clinical trials in oncology. Here, we present a strategy for increasing the therapeutic potential of APO866 through the rescue of normal tissues by coadministration of nicotinic acid (Vitamin B3). We examined the toxicity profile of APO866 in B6D2F1 mice and the effect of oral administration of nicotinic acid on tissue toxicity. Nicotinic acid (50 mg/kg) protects mice from death and severe toxicity from an APO866 dose (60 mg/kg) four times the monotherapy maximum tolerated dose (15 mg/kg). In a panel of six cancer cell lines, we find that three (including ML-2 cells) are protected by nicotinic acid in vitro, whereas the cytotoxicity of APO866 remains unaffected in the remaining three (including A2780 cells). A selective biomarker for the protection by nicotinic acid was subsequently identified by quantitative RT-PCR. The expression of nicotinic acid phosphoribosyltransferase is low in the cell lines not rescued from APO866 by nicotinic acid compared with protected cell lines. The findings in cell lines translated into xenograft models in which the combination of 50 mg/kg nicotinic acid and 50 mg/kg APO866 in mouse xenografts of A2780 cells increased life span by >3-fold compared with standard treatment of 15 mg/kg, and the effect of APO866 was clearly decreased when using the same treatment paradigm in ML-2 xenografts. In conclusion, the combination of high doses of APO866 with rescue by nicotinic acid may significantly increase the therapeutic potential in a subset of cancers with low expression of nicotinic acid phosphoribosyltransferase. Mol Cancer Ther; 9(6); 1609–17. ©2010 AACR.